A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

NCT05896761 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1)

Interventions

DRUG: Cabotegravir Injectable Suspension
DRUG: Rilpivirine Injectable Suspension

Sponsor

ViiV Healthcare

Collaborators

[object Object]